Leukemia therapeutics Market - By Type of Leukemia (Acute lymphocytic leukemia, chronic lymphocytic leukemia, Acute myeloid leukemia, Chronic myeloid leukemia, Leukemia Therapeutics Market) By Treatment Type (Targeted drugs & immunotherapy, Chemotherapy) By Molecule Type (Small Molecules, Biologics) By Mode of Administration (Injectable, Oral) By Gender (Male, Female) By Region (North America, Europe, Asia Pacific, Rest of the World) - Industry Analysis, Opportunity and Forecast 2020 To 2027
Published Date: May 2021
No. of Pages: 196
Status: Published
Report Code: ARI100558
Commercially available drug in the market for the treatment of leukemia includes Gleevec, Bosulif, Sprycel, Iclusig and others. Drugs which are in clinical trials expected to launch in the marketwithin next few (3 to 5)years include Bosutinib, Omapro, ga101/rg7159, Vidaza, Dacogen, Midostaurin, Vosaroxin, Quizartinib, Graspa, Marqibo.
In recent time there is increased use of leukemia therapeutic due to rising number of cancer diseases across the world. Rising aging population, lifestyle factors and increasing awareness for healthcare are some of the key driving factors for the growth of the global leukemia therapeutics market. In addition, innovative and targeted drug delivery is also fuelling the growth of the global leukemia therapeutics market. However, availability of large numbers of generic form of drugs and limited treatment options are some of the major factors restraining the growth of the global leukemia therapeutics market. In addition, high unmet need for diagnosis is also restraining the growth of the global leukemia therapeutics market.
Off label prescribing would support the growth of the global leukemia therapeutics market. In addition, limited number of market players would supports the entry of new market players. Innovative and safer therapies could develop an opportunity for growth of the global leukemia therapeutic market. However, adverse effect caused by chemotherapy and radiation therapy could lead a challenge for the global leukemia therapeutics market.
The major players in this market are AbbVie (US), Bristol-Myers Squibb (US), Novartis (Switzerland, F. Hoffmann-La Roche (Switzerland), Pfizer (US), Sanofi (France), Amgen (US), Gilead Sciences (US), Takeda Pharmaceutical (Japan), and Celgene (US). Product approvals are a key strategy adopted by key players in order to enhance their dominance in this market.
Novartis is leading the global leukemia therapeutics market, owing to its strong sales channel and innovative therapies. The company invested ~17.5% of its revenue for its R&D activities. In May 2018, Novartis launched its CAR-T cell therapy for the second indication—treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma. With the innovative launch of Kymriah, Novartis is now a pioneer of leukemia immune therapies.
Analyst Commentary
Market growth is largely driven by the rising prevalence of acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML) and increasing approvals of novel & innovative drugs and immunotherapies.
Based on type of leukemia, factors such as the large number of treatment options available for the treatment of CML and high incidence rate of CML are significantly driving the growth of this market. For instance, in the US, there were 20,940 CML new cases, as compared to 20,110 in 2017. In addition, the growth of this market segment is driven by the rising geriatric population and increasing funding for cancer research and the development of new therapies.
Owing to the surging demand for targeted drugs, this segment likely to dominate the market during the forecast period. Targeted drugs are most widely used owing to their fewer side effects and higher efficacy and success rate as compared to chemotherapy Owing to these factors, their sales have increased in recent years. For instance, the first FDA-approved immunotherapy for ALL by Novartis registered sales of USD 76 million in 2018 as compared to USD 6 million in 2017. Similarly, the sales for BLINCYTO by Amgen indicated for ALL increased by 37% in the fourth quarter of 2018.
Segmentation
The leukemia therapeutics market is segmented based on type of leukemia, by mode of administration, by gender and by region. On the basis of type of leukemia the market is bifurcated into Acute lymphocytic leukemia (ALL), Chronic lymphocytic leukemia (CLL), Acute myeloid leukemia (AML), Chronic myeloid leukemia (CML), Leukemia Therapeutics Market. On the basis of treatment the market is segmented into Targeted drugs & immunotherapy, Chemotherapy. On the basis of molecule the market is bifurcated into Small Molecules, Biologics.On the basis of mode of administration the market is segmented into Injectable, Oral. On the basis of gender the market is bifurcated into male and female.
Regional Analysis
The countries covered in the global leukemia therapeutics market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific. Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
Among the geographies, North America dominates the global leukemia therapeutics market owing to the rise in the number of patients with cancer, growing genetic mutation, and increased expenditure. In 2016, the American Cancer Society estimates that approximately 60,140 new leukemia cases were diagnosed in the United States. Furthermore, technological advancement, increasing patient awareness, supportive government policies in terms of incentives and investments, sophisticated healthcare infrastructure are the key factors that attribute to the largest revenue in the North America region. Europe is anticipated to hold the second position in the market due to a higher presence of products with no major patent expiration. Asia-Pacific is likely to grow rapidly due to the increasing investments in research and development for the treatment of leukemia and the growing prevalence of leukemia in countries such as Japan and India.
TABLE OF CONTENTS
Chapter 1. Executive Summary
Chapter 2. Research Methodology
2.1. Research approach
2.2. Scope, definition, and assumptions
2.3. Data Sources
2.3.1. Secondary Sources
2.3.1.1. Preliminary data mining
2.3.2. Primary Sources
2.3.2.1. Statistical Model
2.3.2.2. Data Triangulation
2.3.2.3. Research Objective
Chapter 3. Market Outlook
3.1. Introduction
3.2. Key trends
3.2.1. xx
3.3. Market drivers
3.3.1. Impact analysis of Market Drivers
3.4. Market restraints
3.4.1. Impact analysis of Market Restraints
3.5. Market opportunities
3.5.1. Impact analysis of Market Opportunities
3.6. Market Challenges
3.6.1. Impact analysis of Market Trends
3.7. Porter’s Five Forces’ analysis
3.7.1. Bargaining Engine Powered of Suppliers
3.7.2. Bargaining Engine Powered of Buyers
3.7.3. Threat of New Entrant
3.7.4. Threat of Substitutes
3.7.5. High Competitive Rivalry
3.8. Value chain analysis
Chapter 4. COVID-19 Impact On Leukaemia Therapeutics Market
Chapter 5. Global Leukaemia Therapeutics Market Overview, By Types of leukaemia, 2015 - 2027 (USD Billion)
5.1. Global Leukaemia Therapeutics Market Share, By Types of leukaemia, 2015 - 2027 (USD Billion)
5.1.1. Acute lymphocytic leukemia (ALL)
5.1.1.1. Market Size and Projections, 2015 - 2027 (USD Billion)
5.1.1.2. Market Size and Projections, by Region, 2015 - 2027 (USD Billion)
5.1.2. Chronic lymphocytic leukemia (CLL)
5.1.2.1. Market Size and Projections, 2015 - 2027 (USD Billion)
5.1.2.2. Market Size and Projections, by Region, 2015 - 2027 (USD Billion)
5.1.3. Acute myeloid leukemia (AML)
5.1.3.1. Market Size and Projections, 2015 - 2027 (USD Billion)
5.1.3.2. Market Size and Projections, by Region, 2015 - 2027 (USD Billion)
5.1.4. Others
5.1.4.1. Market Size and Projections, 2015 - 2027 (USD Billion)
5.1.4.2. Market Size and Projections, by Region, 2015 - 2027 (USD Billion)
Chapter 6. Global Leukaemia Therapeutics Market Overview, By Mode of Administration, 2015 - 2027 (USD Billion)
6.1. Global Leukaemia Therapeutics Market Share, By Mode of Administration, 2015 - 2027 (USD Billion)
6.1.1. Injectable
6.1.1.1. Market Size and Projections, 2015 - 2027 (USD Billion)
6.1.1.2. Market Size and Projections, by Region, 2015 - 2027 (USD Billion)
6.1.2. ORAL
6.1.2.1. Market Size and Projections, 2015 - 2027 (USD Billion)
6.1.2.2. Market Size and Projections, by Region, 2015 - 2027 (USD Billion)
Chapter 7. Global Leukaemia Therapeutics Market Overview, By Gender, 2015 - 2027 (USD Billion)
7.1. Global Leukaemia Therapeutics Market Share, By Gender, 2015 - 2027 (USD Billion)
7.1.1. Male
7.1.1.1. Market Size and Projections, 2015 - 2027 (USD Billion)
7.1.1.2. Market Size and Projections, by Region, 2015 - 2027 (USD Billion)
7.1.2. Female
7.1.2.1. Market Size and Projections, 2015 - 2027 (USD Billion)
7.1.2.2. Market Size and Projections, by Region, 2015 - 2027 (USD Billion)
Chapter 8. Global Leukaemia Therapeutics Market Overview, By Geography, 2015 - 2027 (USD Billion)
8.1. Global Leukaemia Therapeutics Market Share, By Geography, 2015 - 2027 (USD Billion)
8.1.1. Market Size and projections, by Countries, 2015 - 2027 (USD Billion)
8.1.2. Market Share and CAGR Comparison, by Countries, 2020 & 2027 (%)
Chapter 9. North America Leukaemia Therapeutics Market Overview, By Countries, 2015 - 2027 (USD Billion)
9.1. North America Leukaemia Therapeutics Market Overview, 2015 - 2027 (USD Billion)
9.1.1. Market size and projections, 2015 - 2027 (USD Billion)
9.1.2. North America Leukaemia Therapeutics Market Overview, By Types of leukaemia, 2015 - 2027 (USD Billion)
9.1.3. North America Leukaemia Therapeutics Market Overview, By Mode of Administration, 2015 - 2027 (USD Billion)
9.1.4. North America Leukaemia Therapeutics Market Overview, By Gender, 2015 - 2027 (USD Billion)
9.1.5. North America Leukaemia Therapeutics Market Overview, By Countries, 2015 - 2027 (USD Billion)
9.1.5.1. U.S. Leukaemia Therapeutics Market Overview, 2015 - 2027 (USD Billion)
9.1.5.1.1. Market size and projections, 2015 - 2027 (USD Billion)
9.1.5.1.2. U.S. Leukaemia Therapeutics Market Overview, By Types of leukaemia, 2015 - 2027 (USD Billion)
9.1.5.1.3. Other Segments
9.1.5.2. Canada Leukaemia Therapeutics Market Overview, 2015 - 2027 (USD Billion)
9.1.5.2.1. Market size and projections, 2015 - 2027 (USD Billion)
9.1.5.2.2. Canada Leukaemia Therapeutics Market Overview, By Types of leukaemia, 2015 - 2027 (USD Billion)
9.1.5.2.3. Other Segments
9.1.5.3. Mexico Leukaemia Therapeutics Market Overview, 2015 - 2027 (USD Billion)
9.1.5.3.1. Market size and projections, 2015 - 2027 (USD Billion)
9.1.5.3.2. Mexico Leukaemia Therapeutics Market Overview, By Types of leukaemia, 2015 - 2027 (USD Billion)
9.1.5.3.3. Other Segments
Chapter 10. Europe Leukaemia Therapeutics Market Overview, By Countries, 2015 - 2027 (USD Billion)
10.1. Europe Leukaemia Therapeutics Market Overview, 2015 - 2027 (USD Billion)
10.1.1. Market size and projections, 2015 - 2027 (USD Billion)
10.1.2. Europe Leukaemia Therapeutics Market Overview, By Types of leukaemia, 2015 - 2027 (USD Billion)
10.1.3. Europe Leukaemia Therapeutics Market Overview, By Mode of Administration, 2015 - 2027 (USD Billion)
10.1.4. Europe Leukaemia Therapeutics Market Overview, By Gender, 2015 - 2027 (USD Billion)
10.1.5. Europe Leukaemia Therapeutics Market Overview, By Countries, 2015 - 2027 (USD Billion)
10.1.5.1. Germany
10.1.5.1.1. Market size and projections, 2015 - 2027 (USD Billion)
10.1.5.1.2. Germany Leukaemia Therapeutics Market Overview, By Types of leukaemia, 2015 - 2027 (USD Billion)
10.1.5.1.3. Others Segments
10.1.5.2. France
10.1.5.2.1. Market size and projections, 2015 - 2027 (USD Billion)
10.1.5.2.2. France Leukaemia Therapeutics Market Overview, By Types of leukaemia, 2015 - 2027 (USD Billion)
10.1.5.2.3. Others Segments
10.1.5.3. UK
10.1.5.3.1. Market size and projections, 2015 - 2027 (USD Billion)
10.1.5.3.2. UK Leukaemia Therapeutics Market Overview, By Types of leukaemia, 2015 - 2027 (USD Billion)
10.1.5.3.3. Others Segments
10.1.5.4. Italy
10.1.5.4.1. Market size and projections, 2015 - 2027 (USD Billion)
10.1.5.4.2. Italy Leukaemia Therapeutics Market Overview, By Types of leukaemia 2015 - 2027 (USD Billion)
10.1.5.4.3. Others Segments
10.1.5.5. Spain
10.1.5.5.1. Market size and projections, 2015 - 2027 (USD Billion)
10.1.5.5.2. Spain Leukaemia Therapeutics Market Overview, By Types of leukaemia, 2015 - 2027 (USD Billion)
10.1.5.5.3. Others Segments
10.1.5.6. Rest of Europe
10.1.5.6.1. Market size and projections, 2015 – 2025
10.1.5.6.2. Rest of Europe Leukaemia Therapeutics Market Overview, By Types of leukaemia, 2015 - 2027 (USD Billion)
10.1.5.6.3. Others Segments
Chapter 11. Asia Pacific Leukaemia Therapeutics Market Overview, By Countries, 2015 - 2027 (USD Billion)
11.1. Asia Pacific Leukaemia Therapeutics Market Overview, 2015 - 2027 (USD Billion)
11.1.1. Market size and projections, 2015 - 2027 (USD Billion)
11.1.2. Asia Pacific Leukaemia Therapeutics Market Overview, By Types of leukaemia, 2015 - 2027 (USD Billion)
11.1.3. Asia Pacific Leukaemia Therapeutics Market Overview, By Mode of Administration, 2015 - 2027 (USD Billion)
11.1.4. Asia Pacific Leukaemia Therapeutics Market Overview, By Gender, 2015 - 2027 (USD Billion)
11.1.5. Asia Pacific Leukaemia Therapeutics Market Overview, By Countries, 2015 - 2027 (USD Billion)
11.1.5.1. India
11.1.5.1.1. Market size and projections, 2015 - 2027 (USD Billion)
11.1.5.1.2. India Leukaemia Therapeutics Market Overview, By Types of leukaemia, 2015 - 2027 (USD Billion)
11.1.5.1.3. Other Segments
11.1.5.2. China
11.1.5.2.1. Market size and projections, 2015 - 2027 (USD Billion)
11.1.5.2.2. China Leukaemia Therapeutics Market Overview, By Types of leukaemia, 2015 - 2027 (USD Billion)
11.1.5.2.3. Other Segments
11.1.5.3. Japan
11.1.5.3.1. Market size and projections, 2015 - 2027 (USD Billion)
11.1.5.3.2. Japan Leukaemia Therapeutics Market Overview, By Types of leukaemia, 2015 - 2027 (USD Billion)
11.1.5.3.3. Other Segments
11.1.5.4. South Korea
11.1.5.4.1. Market size and projections, 2015 - 2027 (USD Billion)
11.1.5.4.2. South Korea Leukaemia Therapeutics Market Overview, By Types of leukaemia, 2015 - 2027 (USD Billion)
11.1.5.4.3. Other Segments
11.1.5.5. Rest of Asia Pacific
11.1.5.5.1. Market size and projections, 2015 - 2027 (USD Billion)
11.1.5.5.2. Rest of Asia Pacific Leukaemia Therapeutics Market Overview, By Types of leukaemia, 2015 - 2027 (USD Billion)
11.1.5.5.3. Other Segments
Chapter 12. Middle East & Africa Leukaemia Therapeutics Market Overview, By Countries, 2015 - 2027 (USD Billion)
12.1. Middle East & Africa Leukaemia Therapeutics Market Overview, 2015 - 2027 (USD Billion)
12.1.1. Market size and projections, 2015 - 2027 (USD Billion)
12.1.2. Middle East & Africa Leukaemia Therapeutics Market Overview, By Types of leukaemia, 2015 - 2027 (USD Billion)
12.1.3. Middle East & Africa Leukaemia Therapeutics Market Overview, By Mode of Administration, 2015 - 2027 (USD Billion)
12.1.4. Middle East & Africa Leukaemia Therapeutics Market Overview, By Gender, 2015 - 2027 (USD Billion)
12.1.5. Middle East & Africa Leukaemia Therapeutics Market Overview, By Countries, 2015 - 2027 (USD Billion)
12.1.5.1. GCC
12.1.5.1.1. Market size and projections, 2015 - 2027 (USD Billion)
12.1.5.1.2. GCC Leukaemia Therapeutics Market Overview, By Types of leukaemia, 2015 - 2027 (USD Billion)
12.1.5.1.3. Other Segments
12.1.5.2. South Africa
12.1.5.2.1. Market size and projections, 2015 - 2027 (USD Billion)
12.1.5.2.2. South Africa Leukaemia Therapeutics Market Overview, By Types of leukaemia, 2015 - 2027 (USD Billion)
12.1.5.2.3. Other Segments
12.1.5.3. Rest of Middle East & Africa
12.1.5.3.1. Market size and projections, 2015 - 2027 (USD Billion)
12.1.5.3.2. Rest of Middle East & Africa Leukaemia Therapeutics Market Overview, By Types of leukaemia, 2015 - 2027 (USD Billion)
12.1.5.3.3. Other Segments
Chapter 13. South America Leukaemia Therapeutics Market Overview, By Countries, 2015 - 2027 (USD Billion)
13.1. South America Leukaemia Therapeutics Market Overview, 2015 - 2027 (USD Billion)
13.1.1. Market size and projections, 2015 - 2027 (USD Billion)
13.1.2. South America Leukaemia Therapeutics Market Overview, By Types of leukaemia, 2015 - 2027 (USD Billion)
13.1.3. South America Leukaemia Therapeutics Market Overview, By Gender, 2015 - 2027 (USD Billion)
13.1.4. South America Leukaemia Therapeutics Market Overview, By Countries, 2015- 2026 (USD Billion)
13.1.5. Brazil
13.1.5.1. Market size and projections, 2015 - 2027 (USD Billion)
13.1.5.2. Brazil Leukaemia Therapeutics Market Overview, By Types of leukaemia, 2015 - 2027 (USD Billion)
13.1.5.3. Other Segments
13.1.6. Argentina
13.1.6.1. Market size and projections, 2015 - 2027 (USD Billion)
13.1.6.2. Argentina Leukaemia Therapeutics Market Overview, By Types of leukaemia, 2015 - 2027 (USD Billion)
13.1.6.3. Other Segments
13.1.7. Rest of South America
13.1.7.1. Market size and projections, 2015 – 2027
13.1.7.2. Rest of South America Leukaemia Therapeutics Market Overview, By Types of leukaemia, 2015 - 2027 (USD Billion)
13.1.7.3. Other Segments
Chapter 14. Competitive Landscape
14.1. Competitive environment, 2020
14.2. Strategic framework
14.2.1. Partnership/agreement
14.2.2. Expansion
14.2.3. Mergers & Acquisitions
14.2.4. New Distribution channel development
Chapter 15. Key Vendor Analysis
15.1. AbbVie.
15.1.1. Company overview
15.1.2. Financial performance
15.1.3. Distribution channel Benchmarking
15.1.4. Recent initiatives
15.1.5. SWOT analysis
15.2. Bristol-Myers Squibb
15.2.1. Company overview
15.2.2. Financial performance
15.2.3. Distribution channel Benchmarking
15.2.4. Recent initiatives
15.2.5. SWOT analysis
15.3. Novartis
15.4. F. Hoffmann-La Roche
15.5. Gilead Sciences
15.6. Sanofi
15.7. Amgen
15.8. Gilead Sciences
15.9. Takeda Pharmaceutical
15.10. Celgene
Chapter 16. Leukaemia Therapeutics Market Cost Analysis
16.1. Leukaemia Therapeutics Market Key Raw Material Analysis
16.1.1. Key Raw Material
16.1.2. Price Trend of Key Raw Material
16.1.3. Key Suppliers of Raw Material
16.1.4. Market Concentration Rate of Raw Material
Chapter 17. Industrial Chain, Sourcing Strategy and Downstream Buyers
17.1. Leukaemia Therapeutics Market Industrial Chain Analysis
17.2. Upstream Raw Material Sourcing
17.3. Raw Material Source of Leukaemia Therapeutics Market Major Manufacturers in 2021
17.4. Downstream Buyers
Chapter 18. Marketing Strategy Analysis, Distributors/Traders
18.1. Marketing Channel
18.1.1. Direct Marketing
18.1.2. Indirect Marketing
18.1.3. Marketing Channel Development Trend
18.2. Market Positioning
18.2.1. Pricing Strategy
18.2.2. Brand Strategy
18.2.3. Target Oral
18.3. Distributors/Traders List
Chapter 19. Market Effect Factors Analysis
19.1. Technology Progress/Risk
19.1.1. Substitutes Threat
19.1.2. Technology Progress in Related Distribution channel
19.2. Consumer Needs/Customer Preference Change
19.3. Economic/Political Environmental Change
Chapter 20. Future Outlook of the Market
Disclaimer
List of Figures
1. Market segmentation
2. Value chain analysis
3. Porter’s Five Forces’ analysis
4. Engine Powered of Suppliers
5. Engine Powered of Buyers
6. Threat of New Entrants
7. Threat of Substitute
8. Competitive Rivalry
9. Global Leukaemia Therapeutics Market share, By Types of leukaemia, 2020 & 2027 (%)
10. Global Leukaemia Therapeutics Market share, by Acute lymphocytic leukemia (ALL), By Types of leukaemia, 2020 & 2027 (USD Billion)
11. Global Leukaemia Therapeutics Market share, by Chronic lymphocytic leukemia (CLL) (AML), By Types of leukaemia, 2020 & 2027 (USD Billion)
12. Global Leukaemia Therapeutics Market share, by Acute myeloid leukemia (AML), By Types of leukaemia, 2020 & 2027 (USD Billion)
13. Global Leukaemia Therapeutics Market share, by Others, By Types of leukaemia, 2020 & 2027 (USD Billion)
14. Global Leukaemia Therapeutics Market share, By Mode of Administration, 2020 & 2027 (%)
15. Global Leukaemia Therapeutics Market share, by ORAL, By Mode of Administration, 2020 & 2027 (USD Billion)
16. Global Leukaemia Therapeutics Market share, by Injectable, By Mode of Administration, 2020 & 2027 (USD Billion)
17. Global Leukaemia Therapeutics Market share, by Region, 2020 & 2027 (%)
18. Global Leukaemia Therapeutics Market share, by region, 2020 - 2027(USD Billion)
19. North America Leukaemia Therapeutics Market, 2020 - 2027(USD Billion)
20. North America Leukaemia Therapeutics Market share, by Countries, 2020 & 2027 (%)
21. U.S. Leukaemia Therapeutics Market, 2020 - 2027(USD Billion)
22. Canada Leukaemia Therapeutics Market, 2020 - 2027(USD Billion)
23. Europe Leukaemia Therapeutics Market, 2020 - 2027(USD Billion)
24. Europe Leukaemia Therapeutics Market share, by Countries, 2020 & 2027 (%)
25. Spain Leukaemia Therapeutics Market, 2020 - 2027(USD Billion)
26. UK Leukaemia Therapeutics Market, 2020 - 2027(USD Billion)
27. Italy Leukaemia Therapeutics Market, 2020 - 2027(USD Billion)
28. Germany Leukaemia Therapeutics Market, 2020 - 2027(USD Billion)
29. France Leukaemia Therapeutics Market, 2020 - 2027(USD Billion)
30. Rest of Europe Leukaemia Therapeutics Market, 2020 - 2027(USD Billion)
31. Asia-Pacific Leukaemia Therapeutics Market, 2020 - 2027(USD Billion)
32. Asia-Pacific Leukaemia Therapeutics Market share, by Countries, 2020 & 2027 (%)
33. China Leukaemia Therapeutics Market, 2020 - 2027(USD Billion)
34. India Leukaemia Therapeutics Market, 2020 - 2027(USD Billion)
35. Australia Leukaemia Therapeutics Market, 2020 - 2027(USD Billion)
36. Japan Leukaemia Therapeutics Market, 2020 - 2027(USD Billion)
37. Rest of Asia-Pacific Leukaemia Therapeutics Market, 2020 - 2027(USD Billion)
38. Middle East & Africa Leukaemia Therapeutics Market, 2020 - 2027(USD Billion)
39. Middle East & Africa Leukaemia Therapeutics Market share, by Countries, 2020 & 2027 (%)
40. GCC Leukaemia Therapeutics Market, 2020 - 2027(USD Billion)
41. South Africa Leukaemia Therapeutics Market, 2020 - 2027(USD Billion)
42. Rest Of Middle East & Africa Leukaemia Therapeutics Market, 2020 - 2027(USD Billion)
43. South America Leukaemia Therapeutics Market, 2020 - 2027(USD Billion)
44. Brazil Leukaemia Therapeutics Market, 2020 - 2027(USD Billion)
45. Mexico Leukaemia Therapeutics Market, 2020 - 2027(USD Billion)
46. Argentina Leukaemia Therapeutics Market, 2020 - 2027(USD Billion)
47. Rest Of South America Leukaemia Therapeutics Market, 2020 - 2027(USD Billion)
List of Tables
1. Impact of Market drivers
2. Impact of Market restraints
3. Global Leukaemia Therapeutics Market, 2020-2027 (USD Billion)
4. Leukaemia Therapeutics requirement, by country, 2020-2027, (USD Billion)
5. North America Leukaemia Therapeutics Market, By Types of leukaemia, 2020-2027 (USD Billion)
6. North America Leukaemia Therapeutics Market, By Mode of Administration, 2020-2027 (USD Billion)
7. Europe Leukaemia Therapeutics Market, By Types of leukaemia, 2020-2027 (USD Billion)
8. Europe Leukaemia Therapeutics Market, By Mode of Administration, 2020-2027 (USD Billion)
9. Asia Pacific Leukaemia Therapeutics Market, By Types of leukaemia, 2020-2027 (USD Billion)
10. Asia Pacific Leukaemia Therapeutics Market, By Mode of Administration, 2020-2027 (USD Billion)
11. Middle East & Africa Leukaemia Therapeutics Market, By Types of leukaemia, 2020-2027 (USD Billion)
12. Middle East & Africa Leukaemia Therapeutics Market, By Mode of Administration, 2020-2027 (USD Billion)
13. South America Leukaemia Therapeutics Market, By Types of leukaemia, 2020-2027 (USD Billion)
14. South America Leukaemia Therapeutics Market, By Mode of Administration, 2020-2027 (USD Billion)
15. Global Leukaemia Therapeutics Market, Company Market Share, 2020 & 2027(%)
16. AbbVie : Product Benchmarking
17. AbbVie : Financial Performance
18. Bristol-Myers Squibb : Product Benchmarking
19. Bristol-Myers Squibb : Financial Performance
20. Novartis : Product Benchmarking
21. Novartis : Financial Performance
22. F. Hoffmann-La Roche : Product Benchmarking
23. F. Hoffmann-La Roche : Financial Performance
24. Pfizer : Product Benchmarking
25. Pfizer : Financial Performance
26. Sanofi: Product Benchmarking
27. Sanofi: Financial Performance
28. Amgen : Product Benchmarking
29. Amgen : Financial Performance
30. Gilead Sciences : Product Benchmarking
31. Gilead Sciences : Financial Performance
32. Takeda Pharmaceutical : Product Benchmarking
33. Takeda Pharmaceutical : Financial Performance
34. Celgene : Product Benchmarking
35. Celgene : Financial Performance
The Leading Key Players in Leukemia Therapeutics Market
AbbVie (US)
Bristol-Myers Squibb (US)
Novartis (Switzerland
F. Hoffmann-La Roche (Switzerland)
Pfizer (US)
Sanofi (France)
Amgen (US)
Gilead Sciences (US)
Takeda Pharmaceutical (Japan)
Celgene (US).
